Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes

被引:503
作者
Harel, M
Aharoni, A
Gaidukov, L
Brumshtein, B
Khersonsky, O
Meged, R
Dvir, H
Ravelli, RBG
McCarthy, A
Toker, L
Silman, I
Sussman, JL [1 ]
Tawfik, DS
机构
[1] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel
[2] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel
[3] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel
[4] European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France
基金
以色列科学基金会;
关键词
D O I
10.1038/nsmb767
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Members of the serum paraoxonase (PON) family have been identified in mammals and other vertebrates, and in invertebrates. PONs exhibit a wide range of physiologically important hydrolytic activities, including drug metabolism and detoxification of nerve agents. PON1 and PON3 reside on high-density lipoprotein (HDL, good cholesterol) and are involved in the prevention of atherosclerosis. We describe the first crystal structure of a PON family member, a variant of PON1 obtained by directed evolution, at a resolution of 2.2 Angstrom. PON1 is a six-bladed beta-propeller with a unique active site lid that is also involved in HDL binding. The three-dimensional structure and directed evolution studies permit a detailed description of PON1's active site and catalytic mechanism, which are reminiscent of secreted phospholipase A2, and of the routes by which PON family members diverged toward different substrate and reaction selectivities.
引用
收藏
页码:412 / 419
页数:8
相关论文
共 38 条
[1]   Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization [J].
Aharoni, A ;
Gaidukov, L ;
Yagur, S ;
Toker, L ;
Silman, I ;
Tawfik, DS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :482-487
[2]   Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor [J].
Ahmed, Z ;
Ravandi, A ;
Maguire, GF ;
Emili, A ;
Draganov, D ;
La Du, BN ;
Kuksis, A ;
Connelly, PW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) :24473-24481
[3]   Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - Selective action of human paraoxonase allozymes Q and R [J].
Aviram, M ;
Billecke, S ;
Sorenson, R ;
Bisgaier, C ;
Newton, R ;
Rosenblat, M ;
Erogul, J ;
Hsu, C ;
Dunlop, C ;
La Du, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) :1617-1624
[4]   Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme [J].
Bencharit, S ;
Morton, CL ;
Xue, Y ;
Potter, PM ;
Redinbo, MR .
NATURE STRUCTURAL BIOLOGY, 2003, 10 (05) :349-356
[5]   Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation [J].
Borhani, DW ;
Rogers, DP ;
Engler, JA ;
Brouillette, CG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (23) :12291-12296
[6]   The mechanosensory protein MEC-6 is a subunit of the C-elegans touch-cell degenerin channel [J].
Chelur, DS ;
Ernstrom, GG ;
Goodman, MB ;
Yao, CA ;
Chen, L ;
O'Hagan, R ;
Chalfie, M .
NATURE, 2002, 420 (6916) :669-673
[7]   Pharmacogenetics of paraoxonases: a brief review [J].
Draganov, DI ;
La Du, BN .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) :78-88
[8]   Direct phasing at low resolution of a protein copurified with human paraoxonase (PON1) [J].
Fokine, A ;
Morales, R ;
Contreras-Martel, C ;
Carpentier, P ;
Renault, F ;
Rochu, D ;
Chabriere, E .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2003, 59 :2083-2087
[9]   Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase [J].
Fuhrman, B ;
Volkova, N ;
Aviram, M .
ATHEROSCLEROSIS, 2002, 161 (02) :307-316
[10]   Acetylcholinesterase - A multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease [J].
Greenblatt, HM ;
Dvir, H ;
Silman, I ;
Sussman, JL .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2003, 20 (03) :369-383